So I Tried Ketamine… | Bryan Johnson Podcast

Mike Min, drawing on emergency medicine experience, stresses that fentanyl overdose deaths have roughly doubled year-over-year, making fentanyl the leading cause of death for 18-45 year-olds in the US. Even pills that look like legitimate pharmaceuticals may contain lethal amounts. He describes giving naloxone in the ER and now advocates for community carry. The group discusses that the 'don't die kit' should be as basic as a first aid kit. Bryan commits to getting keychain versions for himself and his daughter. Mike clarifies that naloxone only works on opioid receptors, so it won't harm someone who is unresponsive from a different cause; the worst outcome is acute withdrawal in a chronic opioid user. They also note that test strips can be purchased online easily, and some versions require only a tiny sample of a pill or powder. This protocol is presented as the most urgent takeaway from the entire episode.

Mike Min explains that ketamine is already widely used in emergency medicine and anesthesia because of its excellent safety profile. The recent proliferation of ketamine clinics is driven by robust evidence for rapid antidepressant and anti-suicidal effects. In one study he co-authored, patients received six IV infusions and saw not only mood improvements but also reductions in multiple epigenetic aging clocks, hinting at systemic benefits. He emphasizes that while ketamine can produce powerful dissociative experiences (the ‘K-hole’), lower psycholytic doses are often used for talk therapy. The group discusses that the therapeutic window—analogous to a period of ‘wet cement’—is the key opportunity; therapy should be concentrated in the days following each infusion to reshape trauma-related neural pathways. Bryan’s own Kernel data confirms that brain connectivity remains altered for about 4-5 days before reverting to baseline. The protocol is not a ‘take-and-forget’ drug but a catalyst for active psychological work.

Mike Min draws on mammalian studies showing that the duration of the psychedelic experience correlates with the length of the open window: ketamine’s ~1-hour trip yields days of plasticity, while ibogaine’s 72-hour experience can open a window for months. He uses the analogy of wet cement that gradually hardens. The team specifically discusses how this could be harnessed for longevity: many people struggle with the inertia of behavior change—starting exercise, improving diet, quitting addictions. A well-timed psychedelic session followed by structured integration might provide the ‘energy to overcome the inertia.’ Bryan suggests that with Kernel, they could measure plasticity directly by having him learn a new language or instrument during the window and track cognitive metrics. The protocol is not yet formally tested but is an active area of interest for the Blueprint team.

Mike Min describes the study: researchers administered ketamine plus BCI to mice and observed sustained antidepressant-like behaviors for 8 weeks, compared to ~1 week with ketamine alone. Histology showed stronger synaptic connections in the hippocampus. No human studies exist. The Blueprint team’s excitement stems from the possibility of combining this with their new measurement capabilities (Kernel, epigenetic clocks, cognitive testing). Bryan proposes a self-experiment: ‘We should do a ketamine experiment with this enhanced effect… try to extend the therapeutic window and measure the effect of my plasticity.’ They discuss learning a new language or instrument as a measurable output. The protocol is not recommended for listeners; it is presented as a window into the future of precision psychedelic medicine.

Bryan wore the Kernel headset for several days leading up to a supervised ketamine session, during the infusion, and for days afterward. Before ketamine, his brain activity patterns were highly stable day-to-day. Immediately after the injection, the images show dramatic oscillations and a complete reorganization of connectivity. Over the next 2-4 days, the patterns remained substantially different from baseline, and by day 4-5 they started to return. This is the measurable correlate of the oft-described ‘therapeutic window’—a period of heightened neuroplasticity when the brain is more malleable and receptive to new habits, thoughts, and therapy. The team interprets this using an airport analogy: brain nodes are like airports, and normally there are predictable flight paths. Ketamine picks up all the airports and repositions them, forcing the system to re-route. Mike Min adds that the duration of the window tracks with the duration of the drug itself; longer-acting psychedelics like ibogaine may open a window lasting months, whereas ketamine’s window is days. The data puts a quantifiable, visual stamp on what had been only subjectively reported.

Mike Min describes a study in which mice were given ketamine plus BCI, a DUSP6 inhibitor that ramps up ERK activity. The combination reinforced neural connections in the hippocampus and produced antidepressant behaviors that lasted 8 weeks instead of the usual ~1 week. This suggests that pharmacologically sustaining the ERK pathway could dramatically extend the period of heightened neuroplasticity. The team sees this as a golden opportunity: because they now can measure brain activity with Kernel, they could run an experiment where Bryan takes ketamine with BCI, monitors the brain for days or weeks, and attempts to learn a new language or musical instrument during the extended window to quantify plasticity. This would be a first-of-its-kind controlled self-experiment merging neuroimaging, pharmacology, and behavioral metrics. The eventual hope is that such protocols could be used to facilitate lasting behavioral changes for longevity—breaking entrenched habits, embedding new ones, and possibly improving cognitive reserve.

Mike Min explains that fentanyl, being 100 times stronger than typical opioids by weight, can cause a fatal overdose even when present in a tiny fragment of a pill. The DEA’s 2023 analysis found that 7 out of 10 counterfeit pills contained high doses of fentanyl, and the trend has affected cocaine, MDMA, and fake opioid pills alike. Year-over-year fentanyl deaths have roughly doubled, making it the leading cause of death in the 18-45 demographic. Kate reads a striking stat: ‘Fentanyl poisoning is the leading cause of death for people aged 18 to 45 in the US.’ This shocks the group, as it means a longevity-threatening substance is killing people in their prime, completely outside the usual aging-related diseases. Bryan says he is ‘absolutely inspired’ and will get a keychain version for himself and his daughter. Mike recommends everyone carry nasal naloxone spray and test strips. They emphasize that naloxone is so safe that if you give it to an unconscious person who is not overdosing on opioids, there is no effect; the worst case is waking someone habituated to opioids into acute withdrawal. The consensus is that having a ‘don’t die drug kit’ should be as normalized as carrying a first aid kit.

Mike Min co-authored a study where 20 patients with treatment-resistant depression received six IV ketamine infusions in a clinical setting. Before and after, they provided blood for epigenetic age analysis. Across multiple clocks, biological age estimates dropped: PhenoAge by 2 years, GrimAge by 1.1 years, OmicAge by 1 year, and a brain-specific clock by 1.5 years. Inflammatory and metabolic markers also trended down. While the sample is small and uncontrolled, Mike leans toward the interpretation that the reduction is secondary to massive improvement in depression symptoms (~50% reduction in severity). He points out that if you lift someone out of severe depression, they likely make better lifestyle choices—sleep, diet, social connection—which could slow or reverse epigenetic aging. However, a direct ketamine effect on aging pathways cannot be ruled out. The group notes that this underscores the need for more studies that integrate mental health and longevity biomarkers, and that their own planned experiments with Kernel could add a brain-activity dimension to such investigations.

Mike Min cites multiple studies: heavy cocaine users face 4-8 times higher mortality risk, equating to a 20-40% reduction in life expectancy. One analysis translates daily cocaine use to an average of 10.8 life-years lost. The mechanisms are dual: cocaine acutely raises blood pressure and sympathetic tone, and it independently promotes arterial plaque formation, accelerating cardiovascular disease. Even when compared to smoking, the mortality numbers are similar or worse. The only medical use Mike can think of is as a topical vasoconstrictor for severe nosebleeds—he recounts hospitals keeping cocaine powder in locked cabinets that require multiple sign-offs to access. Bryan’s conclusion: ‘Probably not going to include blow in the protocol.’